Mitchell S. von Itzstein

589 total citations
32 papers, 344 citations indexed

About

Mitchell S. von Itzstein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Mitchell S. von Itzstein has authored 32 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Mitchell S. von Itzstein's work include Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Mitchell S. von Itzstein is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Mitchell S. von Itzstein collaborates with scholars based in United States, Australia and Italy. Mitchell S. von Itzstein's co-authors include David E. Gerber, Shaheen Khan, Yang Xie, Jennifer A. Whitaker, Farjana Fattah, Helen Mayo, Edward K. Wakeland, Gregory A. Poland, Rong Lü and Quan‐Zhen Li and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Mitchell S. von Itzstein

32 papers receiving 341 citations

Peers

Mitchell S. von Itzstein

ONCOL

PRM

IMMUN

EPIDE

Pei‐Wei Huang Taiwan

Danielle Benedict Sacdalan Philippines

Angélique Vienot France

Mingjia Li United States

Baptiste Abbar France

Débora S. Bruno United States

Claudio Flores Peru

Alessandro De Toma Italy

Luis Miguel Juárez‐Salcedo Spain

Dinesh de Alwis United States

Pei‐Wei Huang Taiwan

Mitchell S. von Itzstein

175 ×0.8

ONCOL

77 ×0.8

PRM

47 ×0.8

IMMUN

37 ×0.8

EPIDE

51 ×1.2

Citations per year, relative to Mitchell S. von Itzstein Mitchell S. von Itzstein (= 1×) peers Pei‐Wei Huang

Countries citing papers authored by Mitchell S. von Itzstein

Since Specialization

Citations

This map shows the geographic impact of Mitchell S. von Itzstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell S. von Itzstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell S. von Itzstein more than expected).

Fields of papers citing papers by Mitchell S. von Itzstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell S. von Itzstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell S. von Itzstein. The network helps show where Mitchell S. von Itzstein may publish in the future.

Co-authorship network of co-authors of Mitchell S. von Itzstein

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell S. von Itzstein. A scholar is included among the top collaborators of Mitchell S. von Itzstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell S. von Itzstein. Mitchell S. von Itzstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Itzstein, Mitchell S. von, Suzanne E. Dahlberg, David E. Gerber, et al.. (2025). Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer. The Oncologist. 30(3). 1 indexed citations

Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8597–8597. 1 indexed citations

Pabani, Aliyah, Mitchell S. von Itzstein, Run Fan, et al.. (2024). Use of artificial intelligence chatbots in clinical management of immune-related adverse events. Journal for ImmunoTherapy of Cancer. 12(5). e008599–e008599. 14 indexed citations

Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 31(4). 639–648. 1 indexed citations

Itzstein, Mitchell S. von, Yiqing Wang, David Hsiehchen, et al.. (2024). Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice. Frontiers in Immunology. 15. 1351739–1351739. 2 indexed citations

Itzstein, Mitchell S. von, Farjana Fattah, Jialiang Liu, et al.. (2024). Distinct autoantibody profiles across checkpoint inhibitor types and toxicities. OncoImmunology. 13(1). 2351255–2351255. 5 indexed citations

Ostmeyer, Jared, Jason Y. Park, Mitchell S. von Itzstein, et al.. (2023). T-cell tolerant fraction as a predictor of immune-related adverse events. Journal for ImmunoTherapy of Cancer. 11(8). e006437–e006437. 4 indexed citations

Ulndreaj, Antigona, Davor Brinc, Mehmet Altan, et al.. (2022). Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study. Clinical Chemistry and Laboratory Medicine (CCLM). 61(1). 154–161. 2 indexed citations

Gerber, David E., et al.. (2022). Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report. JTO Clinical and Research Reports. 3(3). 100291–100291. 4 indexed citations

10.

Itzstein, Mitchell S. von, Yiqing Wang, Thomas Sheffield, et al.. (2022). Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. Cancer Immunology Immunotherapy. 71(9). 2169–2181. 24 indexed citations

11.

Itzstein, Mitchell S. von, et al.. (2022). Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report. JTO Clinical and Research Reports. 3(8). 100368–100368. 2 indexed citations

12.

Itzstein, Mitchell S. von, David Hsiehchen, Hui Yang, et al.. (2022). Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era. Clinical Lung Cancer. 24(1). 11–17. 6 indexed citations

13.

Itzstein, Mitchell S. von, Arjun Gupta, Kemp H. Kernstine, et al.. (2020). Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?. PLoS ONE. 15(4). e0231258–e0231258. 3 indexed citations

14.

Itzstein, Mitchell S. von, Michael Burke, Rolf A. Brekken, et al.. (2020). Targeting TAM to Tame Pancreatic Cancer. Targeted Oncology. 15(5). 579–588. 6 indexed citations

15.

Khan, Shaheen, Mitchell S. von Itzstein, Rong Lü, et al.. (2020). Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's-Like Phenomenon. The Oncologist. 25(5). e753–e757. 14 indexed citations

16.

Itzstein, Mitchell S. von, et al.. (2020). Immunotherapy Use in Patients With Lung Cancer and Comorbidities. The Cancer Journal. 26(6). 525–536. 16 indexed citations

17.

Wang, Shidan, Mitchell S. von Itzstein, Lin Yang, et al.. (2019). Type and case volume of health care facility influences survival and surgery selection in cases with early‐stage non–small cell lung cancer. Cancer. 125(23). 4252–4259. 18 indexed citations

18.

Itzstein, Mitchell S. von, Arjun Gupta, Kristin C. Mara, Sahil Khanna, & David E. Gerber. (2019). Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. Lung. 197(5). 593–599. 6 indexed citations

19.

Whitaker, Jennifer A., Mitchell S. von Itzstein, & Gregory A. Poland. (2018). Strategies to maximize influenza vaccine impact in older adults. Vaccine. 36(40). 5940–5948. 15 indexed citations

20.

Itzstein, Mitchell S. von, et al.. (2017). Severe destructive nasopharyngeal granulomatosis with polyangiitis with superimposed skull base Pseudomonas aeruginosa osteomyelitis. BMJ Case Reports. 2017. bcr–2017. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact